SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that…
Biotechnology
US, Stamford [HQ]
Cash Flow Statement
6 Sheets · From 2023 to 2018Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Operating Cash Flow (OCF) | -14.00 | -47.00 | -32.00 | -127.00 | -161.00 | -222.00 | |
| Operating Cash (Net) | -14.00 | -47.00 | -32.00 | -127.00 | -161.00 | -222.00 | |
| Accounts Receivable | - - | - - | - - | - - | - - | -5.00 | |
| Accounts Payable | - - | 1.00 | -1.00 | 2.00 | 4.00 | - - | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | |
| Change | 2.00 | 4.00 | 1.00 | 5.00 | 38.00 | - - | |
| Other WC | 1.00 | 3.00 | 2.00 | 3.00 | 33.00 | 9.00 | |
| Investing Activities | |||||||
| Used Cash (Net) | - - | -4.00 | -418.00 | 83.00 | -215.00 | 34.00 | |
| Capital Expenditure | - - | - - | - - | -2.00 | -10.00 | -7.00 | |
| Purchases of Investments | - - | -3.00 | -442.00 | -305.00 | -481.00 | -575.00 | |
| Sale/Maturity of Investment | - - | 3.00 | 28.00 | 391.00 | 279.00 | 620.00 | |
| Property, Plant, Equipment (P&PE) | - - | - - | - - | -2.00 | -10.00 | -7.00 | |
| Acquisitions (Net) | - - | -3.00 | -3.00 | 2.00 | -4.00 | -2.00 | |
| Other Investing Activities | - - | - - | -418.00 | -2.00 | -205.00 | 42.00 | |
| Financing Activities | |||||||
| Used Cash (Net) | -50.00 | -333.00 | -270.00 | -1.00 | -340.00 | -296.00 | |
| Debt Repayment | - - | - - | - - | - - | - - | - - | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | - - | 343 | 302 | |
| Issued | - - | 169.00 | 269.00 | 1.00 | 342.00 | 299.00 | |
| Repurchased | - - | - - | - - | - - | -1.00 | -2.00 | |
| Other Financing Activities | 50.00 | 163.00 | - - | - - | 342.00 | - - | |
| Cash Balances | |||||||
| Begin of Period | 10.00 | 46.00 | 328.00 | 147.00 | 104.00 | 68.00 | |
| End of Period | 45.00 | 328.00 | 147.00 | 104.00 | 68.00 | 176.00 | |
| Change | 35.00 | 282.00 | -180.00 | -43.00 | -36.00 | 108.00 | |
| Non-Cash Balances | |||||||
| Depreciation and Amortization | - - | - - | - - | - - | - - | 1.00 | |
| Stock Based Compensation | - - | 3.00 | 10.00 | 38.00 | 72.00 | 94.00 | |
| Other | - - | 2.00 | 1.00 | - - | 4.00 | -2.00 | |
| Highlighted metrics | |||||||
| Free Cash Flow (FCF) | -14.00 | -48.00 | -32.00 | -129.00 | -171.00 | -230.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | -1,411.00 | - - | -1,542.00 | -3,315.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
|||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - |